Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Lipella Pharmaceuticals, Inc. ( (LIPO) ) has shared an announcement.
On February 6, 2025, Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus (OLP), a condition affecting around 6 million Americans with no current FDA-approved therapies. This approval marks a significant milestone, enabling wider patient access and supporting ongoing clinical trials. The company plans to present positive Phase 2a results of LP-310 at the BIO CEO & Investor Conference on February 11, 2025, highlighting its potential as a new treatment option.
More about Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for diseases with significant unmet medical needs. They specialize in reformulating active agents in existing generic drugs, targeting conditions with no approved treatments.
YTD Price Performance: -4.09%
Average Trading Volume: 1,595,304
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.71M
For a thorough assessment of LIPO stock, go to TipRanks’ Stock Analysis page.
